[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1966

Topical Guanethidine Therapy for Endocrine Lid Retraction

Author Affiliations

St. Louis
From the Department of Ophthalmology and The Oscar Johnson Institute, Washington University School of Medicine, St. Louis.

Arch Ophthalmol. 1966;76(3):364-367. doi:10.1001/archopht.1966.03850010366012
Abstract

Lid retraction, Dalrymple's sign, is one of the very common eye signs of Graves' disease often occurring after therapy has restored the euthyroid state as well as during the initial thyrotoxic attack. It may be unilateral or bilateral, symmetrical or asymmetrical. Exophthalmos may exist, but is not necessarily present. In addition to being a very troublesome cosmetic problem, lid retraction results in conjunctivitis and keratitis secondary to exposure and dehydration. Prolonged, untreated retraction may eventually lead to corneal ulceration and permanent scarring. Recently a new surgical approach for correction of lid retraction has been described.1

In 19642 it was reported that one drop of a 10% guanethidine solution instilled in the eyes of normal patients caused a partial Horner's syndrome consisting of miosis, ptosis, and slight conjunctival vascular dilatation in the treated eye. Other ocular and systemic side effects were absent. Similarly, in 1961,3 no adverse side

First Page Preview View Large
First page PDF preview
First page PDF preview
×